key: cord-0764149-vmof26q4
authors: Zhao, Yinghua; Sui, Liyan; Wu, Ping; Wang, Wenfang; Tan, Guangyun; Wang, Zedong; Yu, Yang; Hou, Zhijun; Wang, Guoqing; Liu, Quan
title: SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses
date: 2021-02-18
journal: bioRxiv
DOI: 10.1101/2021.02.17.431755
sha: 6b7e59122acc3e776f02b64e3a4607b4e31d6708
doc_id: 764149
cord_uid: vmof26q4

The recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing global pandemic of COVID-19, may trigger immunosuppression in the early stage and a cytokine storm in the late stage of infection, however, the underlying mechanisms are not well understood. Here we demonstrated that the SARS-CoV-2 nucleocapsid (N) protein dually regulated innate immune responses, i.e., the low-dose N protein suppressed type I interferon (IFN-I) signaling and inflammatory cytokines, whereas high-dose N protein promoted IFN-I signaling and inflammatory cytokines. Mechanistically, the SARS-CoV-2 N protein interacted with the tripartite motif protein 25 (TRIM25), thereby dually regulating the phosphorylation and nuclear translocation of IRF3, STAT1 and STAT2. Additionally, low-dose N protein combined with TRIM25 could suppress retinoic acid-inducible gene I (RIG-I) ubiquitination and activation. Our findings revealed a regulatory mechanism of innate immune responses by the SARS-CoV-2 N protein, which would contribute to understanding the pathogenesis of SARS-CoV-2 and other SARS-like coronaviruses, and development of more effective strategies for controlling COVID-19.

In the first stage, viral infection is rapidly sensed by host PRRs, whose signal cascades 115 phosphorylates and dimerizes the transcription factor IRF3 (interferon regulatory factor 3), 116 followed by entering the nucleus to activate the expression of . In the second stage, 117 secreted IFN-α/β triggers the Janus kinases/signal transducer activator transcription proteins 118 (JAK/STAT) 1 and 2 signaling pathways. Phosphorylated STAT1 and STAT2 can form 119 heterodimers, then combine with IRF9 (interferon regulatory factor 9) to form transcription 120 complex ISGF3 (IFN-stimulated gene factor 3), which translocates to the nucleus to induce 121 IFN-stimulated genes (ISGs), and ultimately elicit an effective antiviral responses (15) . 122

In order to investigate the mechanism of the dually regulated IFN-I signaling by 123 SARS-CoV-2 N protein, we tested the expression and activation of endogenous IRF3, STAT1 and 124 STAT2 upon N protein and poly(I:C) induction. HEK293T cells were transfected with a 125 8 significantly inhibited poly(I:C) induced nuclear translocation of IRF3 (Fig. 3B ). Then we tested 159 the co-localization and nuclear transfer of STAT1 and STAT2 in the presence of different doses of 160 N proteins. SARS-CoV-2 and SARS-CoV N proteins were co-localized with STAT1 and STAT2 161 in the cytoplasm (Fig. S3 ). The nuclear transfer of STAT1 and STAT2 were significantly 162 enhanced by high-dose (1 μg) N proteins without poly(I:C) stimulation (Fig. 3C , E), whereas they 163 were inhibited by low-dose (0.25 μg) N proteins in the presence of poly(I:C) stimulation (Fig. 3D , 164 F). These findings indicated that both SARS-CoV-2 and SARS-CoV N proteins dually regulate the 165 nuclear translocation of IRF3, STAT1 and STAT2. 

Results shown are the mean ± SD of at least three independent experiments. *P < 0.05, **P < 0.01, and ***P < 208 0.001; two-tailed Student's t-test.

proteins can interfere with the association between TRIM25 and RIG-I by interacting with 212 TRIM25 (22, 23). To determine whether the SARS-CoV-2 N protein specifically binds to 213 TRIM25, we co-transfected SARS-CoV-2 N protein and TRIM25 into HEK293T cells. After 24 h 214 post-transfection, the cell lysates were subjected to immunoprecipitation (IP). We found that 215 12 ubiquitination. HEK293T cells were transfected with RIG-I and ubiquitin plasmids together with 248 SARS-CoV-2 N protein. The results indicated that RIG-I ubiquitination was significantly impaired 249 by SARS-CoV-2 N protein in a dose-dependent manner (Fig. 6A) , which was also confirmed by 250 the immunofluorescence analysis (Fig. 6B) . We further analyzed whether this ubiquitination 251 inhibitory was mediated by TRIM25, and found that TRIM25 over-expression rescued the 252 suppression of RIG-I ubiquitination caused by SARS-CoV-2 N protein (Fig. 6C ). In addition, the 253 RIG-I ubiquitination was reduced in TRIM25-knockout cells, and the inhibition of RIG-I 254 ubiquitination by SARS-CoV-2 N protein was also abolished (Fig. 6D) . These results indicated 255 that SARS-CoV-2 N protein inhibits RIG-I ubiquitination through interfering with the interaction 256 of TRIM25 and RIG-I. 

N is responsible for suppression of IFN-I production (23). We investigated which domain of 269 SARS-CoV-2 N protein is involved in its interaction with TRIM25. Full-length or truncated 270 fragments (aa 1 to 360 and 361 to 419) of SARS-CoV-2 N protein were co-transfected with 271 TRIM25 into 293T cells. We found that both truncated proteins can bind to TRIM25 (Fig. 7A) , 272

and were sufficient to suppress IFN-I production (Fig. 7B, C) . To determine the key domains for 273 the truncated protein of 1 to 360 aa, we then constructed a series of truncations (Fig. 7F) . The 274

protein-protein interactions of these truncations with TRIM25 were examined via co-IP assays, 275 demonstrating that the truncations (aa 1-175 and 252-360) of SARS-CoV-2 N protein can interact 276 with TRIM25, but the truncation of aa 176-251 did not work (Fig. 7D, E) . 277

As a ubiquitin E3 ligase, TRIM25 includes a RING-finger domain, a SPRY domain, a 278 coiled-coil dimerization domain, and two B-box domains (24). Reciprocally, plasmids expressing 279 SPRY, SPRY deletion and RING-finger deletion truncations were constructed (Fig. 7I) . We found 280 that SARS-CoV-2 N protein was co-localized with SPRY domain of TRIM25 in the cytoplasm, 281 which is same as SARS-CoV N protein (23) (Fig. 7G, Fig. S4D ). In addition, co-IP results showed 282 that SARS-CoV-2 N protein can interact with both the SPRY-and RING-deleted TRIM25 283 truncations with the lower binding level than that of full-length TRIM25 (Fig. 7H, Fig. S4A and 284 S4B), indicating that SARS-CoV-2 N protein can interact with the SPRY and other domains of 285 TRIM25, including the RING-finger domain, while only SPRY domain of TRIM25 is responsible 286 for the interaction with SARS-CoV N protein (Fig. S4C-E) . These findings clearly defined the 287 interaction domains of the SARS-CoV N protein and TRIM25 (Fig. 7F, I) . 288

We unexpectedly found that the expression of both SARS-CoV-2 N protein and SPRY 289 domain was obviously reduced in the co-transfected cells (Fig. 7H, Fig. S4A, S4B) , while the 290 mRNA levels of the SARS-CoV-2 N and SPRY were increased (Fig. 7J ). Unlike inhibition of 291 TRIM25-induced IFN-I production, SARS-CoV-2 N protein enhanced the SPRY domain-induced 292 IFN-I production (Fig. S5A) , suggesting that SARS-CoV-2 N and SPRY may be degraded by inflammation, hemodynamic instability, hyperferritinemia, and multi-organ failure (30) (31) (32) . 367

Moreover, both SARS-CoV and MERS-CoV infections can trigger the cytokine storm that 368 contribute to occurrence of ARDS and is the leading cause of death (33, 34). The proinflammatory 369 cytokines IL1B, IL6, IL18, IFNγ, and TNFA are the key components of cytokine storm in the 370 coronavirus infections (35). For example, IL6 is closely correlated with ARDS severity and blood 371 viral load of 37) . Our study showed high-dose (1 μg) SARS-CoV-2 N protein can 372 promote expression of IL6, IL1B, and TNFA, demonstrating that SARS-CoV-2 N protein was 373 involved in the cytokine storm of COVID-19. 374

Low-dose SARS-CoV-2 N protein inhibited RIG-I ubiquitination through interacting with 375 TRIM25 to suppress IFN-I production. In TRIM25 knockout cells, the regulatory effect of 376 high-dose N protein was exactly opposite to that of WT cells (Fig. S6) , indicating that high-dose 377 SARS-CoV-2 N protein also activated IFN-I signaling through TRIM25. However, the two-way 378 regulation mechanism of TRIM25 is needed further investigation. 379

Our results also showed that high-dose SARS-CoV N protein could promote innate immune 380 response by promoting IRF3/STAT1/STAT2 phosphorylation and nuclear translocation. In 381 addition, low-dose SARS-CoV N protein inhibited IFN-I production through TRIM25, whereas 382 high-dose N protein enhanced IFN-I production through TRIM25 (Fig. S6 ). Considering that both 383 SRAS-CoV and MERS-CoV N proteins can inhibit IFN-I production through interacting with 384 TRIM25(22, 23), we speculate that the N proteins of SARS-like coronaviruses have the common 385 ability to dually regulate innate immune response. 386

In summary, we demonstrated that the SARS-CoV-2 N protein dually regulates innate 387 immune responses, in which the low-dose N protein suppresses type I interferon (IFN-I) signaling 388 and inflammatory cytokines, whereas high-dose N protein promotes IFN-I signaling and 389 inflammatory cytokines. The SARS-CoV-2 N protein interacts with TRIM25, thereby dually 390 regulating the phosphorylation and nuclear translocation of IRF3, STAT1 and STAT2. Our 391 findings reveal a regulatory mechanism of innate immune responses mediated by the

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent 496 interferon antagonists

Activation and evasion of type I interferon responses by 499 SARS-CoV-2

Structural basis for translational 503 shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

The pathogenesis and treatment of the `Cytokine Storm' in 505 COVID-19

A virological view of innate immune recognition

CARD of human RIG-I provide mechanistic insights into regulation of RIG-I 539 activation

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

glycoprotein M antagonizes the MAVS-mediated innate antiviral response

Evasion of Type I Interferon by SARS-CoV-2

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist 551

Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication

Type-I-IFN-Stimulated Gene TRIM5gamma Inhibits HBV Replication by 586

Dectin-1-activated dendritic cells trigger potent antitumour 589 immunity through the induction of Th9 cells

Inhibition of HDAC6 by tubastatin A disrupts 591 mouse oocyte meiosis via regulating histone modifications and mRNA expression

The authors declare that they have no conflict of interest. 461 462